Novartis (NVS) option IV steady into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Novartis (NVS) PT Raised to $108 at CFRA
April 23, 2024 1:11 PM EDTCFRA analyst Wan Nurhayati raised the price target on Novartis (NYSE: NVS) to $108.00 (from $105.00) while maintaining a Hold rating.
The analyst comments "We raise our target price by $3 to $108, implying a 2024 P/E of 15.4x, largely in line with the peer average. Novartis... More
